Viral lineages that predominate are those that spread faster, evade existing immunity more effectively, or both. At any given time, one or two lineages of major respiratory viruses like influenza and SARS-CoV-2 dominate global circulation, and they get replaced when a new variant emerges with a meaningful fitness advantage. The pattern repeats on a cycle that ranges from a few months to several years depending on the virus.
What Makes a Lineage Dominant
A viral lineage rises to dominance through two main routes: it can outrun the existing dominant strain by transmitting more efficiently, or it can sidestep the immune defenses that most people have built up from prior infections and vaccines. Often, a successful new lineage does both at once, though the balance between these two advantages shifts depending on how much immunity exists in the population.
When a virus is circulating in a largely unprotected population, raw transmissibility matters most. The lineage that spreads fastest wins. But as more people develop immunity through infection or vaccination, the selective pressure shifts. Lineages that can partially dodge antibodies from prior exposures gain a growing edge, even if they aren’t inherently more transmissible in a naive host. This two-phase dynamic plays out repeatedly: first the virus optimizes for spread, then it optimizes for immune escape.
The growth advantage of a new lineage can be quantified by comparing its effective reproduction number to the strain it’s replacing. When Delta displaced earlier SARS-CoV-2 variants in 2021, it held a growth advantage of roughly 1.6 to 2.0 across U.S. states. When Omicron arrived later that year, its initial growth advantage ranged from 2.0 to 4.4, with an effective reproduction number between 2 and 3 in December 2021. That massive edge meant Omicron could fuel an explosive wave even while Delta was still circulating widely. By contrast, the Mu variant had some immune escape ability but lacked the overall fitness to outcompete Delta in any U.S. state it was tracked in.
SARS-CoV-2: Rapid Lineage Turnover
SARS-CoV-2 has shown remarkably fast lineage replacement. Since Omicron emerged in late 2021, dominant sub-lineages have been cycling through roughly every three to six months. The XBB.1.5 sub-lineage dominated through much of 2023, then JN.1, which carried substantial genetic differences from XBB descendants, became the predominant lineage nationally by January 2024 and held that position through late April 2024 before its own descendants began taking over.
The Omicron family illustrates how different advantages drive each transition. BA.1 was 78% more transmissible than Delta and also showed significant immune escape: vaccinated individuals who were more than five months past their last dose had nearly twice the odds of being infected with BA.1 compared to Delta. BA.1’s spike protein was so different from earlier variants that it essentially opened a new antigenic space, sharply reducing the protection offered by vaccines designed against the original virus. When BA.2 then replaced BA.1, the mechanism was different. BA.2 didn’t show better immune escape among recently vaccinated people. Instead, it reached susceptible individuals faster and produced higher viral loads in early-stage infections, giving it a pure speed advantage.
Influenza: A Slower, Seasonal Rotation
Influenza lineage dominance operates on a longer timescale. Two subtypes of influenza A, H3N2 and H1N1, alternate in dominance from season to season, and each flu season is typically characterized by one subtype driving the majority of cases. The 2016-2017 season in Korea, for example, was H3N2-dominant, while the 2018-2019 season was H1N1-dominant. Which subtype predominates in a given year depends on how much population immunity exists against each, combined with the specific mutations the virus has acquired since last season.
These two subtypes also produce somewhat different illness profiles. H3N2-dominant seasons tend to produce higher fevers: 60% of patients ran temperatures at or above 38°C during the H3N2-dominant 2016-2017 season, compared to 47% during the H1N1-dominant 2018-2019 season. However, H1N1 seasons bring more body aches, cough, and sore throat. Myalgia affected 72% of patients during the H1N1 season versus 48% during the H3N2 season, and cough rates were 64% versus 41%. Fever also resolved faster with antiviral treatment during H3N2 seasons, with 72% of patients seeing fever clear within 24 hours compared to just 30% during the H1N1 season. Hospitalization and pneumonia rates were similarly low in both seasons.
Influenza B has historically circulated as two lineages: Victoria and Yamagata. But the B/Yamagata lineage has not been detected in global surveillance since March 2020 and is no longer considered actively circulating. The CDC recommended that all U.S. flu vaccines for the 2024-2025 season shift from four-component to three-component formulas, dropping the Yamagata component entirely. This leaves B/Victoria as the sole circulating influenza B lineage.
How Antigenic Drift Fuels Replacement
The molecular engine behind lineage turnover is antigenic drift: the gradual accumulation of mutations in the proteins that sit on the virus’s surface and serve as the main targets for antibodies. In influenza, the key protein is hemagglutinin, which the virus uses to latch onto cells. Just a few amino acid changes near the receptor binding site on hemagglutinin can create what researchers call a new “antigenic cluster,” effectively making the virus look unfamiliar enough to slip past existing antibodies. These cluster transitions happen roughly every 2 to 10 years for influenza A.
What makes lineage prediction so difficult is that the effect of any single mutation depends heavily on which other mutations are already present. A change that does nothing in one viral strain can become a potent escape mutation when it appears alongside other changes. This interaction between mutations, called epistasis, means that two amino acid changes that are individually harmless can combine to create a virus that evades a broad range of antibodies. Deep mutational scanning experiments on H1 influenza have confirmed that different viral strains face different barriers to immune escape, and that mutations in the receptor binding site interact with each other in ways that are hard to predict from any single change alone.
The Role of Immunity in Shaping Dominance
Widespread vaccination doesn’t just protect individuals. It reshapes the competitive landscape that viral lineages face. As more people carry antibodies against specific viral proteins, lineages that can partially evade those antibodies gain a selective advantage. This doesn’t mean vaccines cause more dangerous variants to emerge. Even when vaccination has driven the evolutionary advantage of certain variants, the overall spread of infection has still been reduced. No documented case exists of a vaccine-driven variant that both spreads regardless of vaccine coverage and compromises the vaccine’s ability to control infection.
The practical effect is that dominant lineages tend to shift more quickly in populations with high levels of mixed immunity from both vaccination and natural infection. Each new wave of immunity narrows the pool of susceptible hosts for the currently dominant strain while opening opportunities for variants that look different enough to partially bypass that immunity.
Climate and Timing
Environmental conditions also influence which lineages circulate and when. Humidity, temperature, and wind affect how respiratory droplets behave in the air, altering how long they stay airborne and how quickly they evaporate. These factors help explain the strong seasonality of respiratory viruses in temperate climates. Absolute humidity in particular has been linked to the seasonal timing of influenza-like illness, and temperature and humidity both contribute to predicting the severity of lower respiratory infections in children. While climate doesn’t determine which specific lineage dominates, it creates the seasonal windows during which lineage competition plays out most intensely, concentrating transmission into periods when conditions favor airborne spread.